Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250022/S002

Volt PFA System

ABBOTT MEDICAL · Decision date Oct 15, 2026

MEDTECHLEDGER EXPLANATIONP250022/S002

What did the FDA approve?

The FDA database entry records approval of a post-approval study protocol for the Volt PFA System (PMA P250022, supplement S002) under the Normal 180 Day Track with no user fee. The recorded purpose is to comply with conditions in the original approval order for P250022. The device category is a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation, product code QZI, cardiovascular specialty, applicant Abbott Medical. The approval applies to the PAS protocol, not to the entire system.

The database shows the supplemental reason as Postapproval Study Protocol, but does not describe the study's design, endpoints, enrollment, or timeline, and provides no new safety or effectiveness findings. The statement's stated compliance purpose does not independently show that any condition has been met. Because the entry identifies the supplement as S002 of P250022, it is a supplement to that PMA rather than a separate original approval.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250022
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Oct 15, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250022/S002
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Oct 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P250022. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250022/S002 received

    Application receipt date recorded by FDA.

  2. P250022/S009 · Related supplement

    Volt PFA Catheter, Sensor Enabled

  3. P250022/S012 · Related supplement

    VOLT PFA CATHETER, SENSOR ENABLED

  4. P250022/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250022

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalDec 19, 2025FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records